Sökning: WFRF:(Scambia Giovanni)
> (2010-2014) >
Efficacy and safety...
Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer
-
Gonzalez-Martin, Antonio (författare)
-
Gladieff, Laurence (författare)
-
- Tholander, Bengt (författare)
- Uppsala universitet,Enheten för onkologi
-
visa fler...
-
Stroyakovsky, Daniel (författare)
-
Gore, Martin (författare)
-
Scambia, Giovanni (författare)
-
Kovalenko, Nadezhda (författare)
-
Oaknin, Ana (författare)
-
Ronco, Julian Perez (författare)
-
Freudensprung, Ulrich (författare)
-
Pignata, Sandro (författare)
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2013
- 2013
- Engelska.
-
Ingår i: European Journal of Cancer. - : Elsevier BV. - 0959-8049 .- 1879-0852. ; 49:18, s. 3831-3838
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Purpose: The single-arm OCTAVIA study evaluated front-line bevacizumab plus weekly paclitaxel and q3w carboplatin. Patients and methods: Patients with newly diagnosed ovarian cancer (International Federation of Gynecology and Obstetrics [FIGO] stage IIb-IV or grade 3/clear-cell stage I/IIA) received bevacizumab (7.5 mg/kg, day 1), weekly paclitaxel (80 mg/m(2) days 1, 8, 15) and carboplatin (area under the curve 6 [AUC6], day 1) intravenously q3w for 6-8 cycles, followed by single-agent bevacizumab (total 1 year). The primary objective was to demonstrate median progression-free survival (PFS) > 18 months according to the lower 90% confidence limit. Secondary end-points included objective response rate, overall survival, safety and tolerability. Results: Most (74%) of the 189 treated patients had stage IIIC/IV disease, similar to the ICON7 population. Patients received a median of six chemotherapy and 17 bevacizumab cycles. At the predefined cutoff 24 months after last patient enrolment, 99 patients (52%) had progressed and 19 (10%) had died, all from ovarian cancer. Median PFS was 23.7 months (95% confidence interval [CI], 19.8-26.4 months), 1-year PFS rate was 85.6%, Response Evaluation Criteria in Solid Tumors (RECIST) response rate was 84.6% and median response duration was 14.7 months. Most patients (>= 90%) completed at least six chemotherapy cycles. Grade >= 3 peripheral sensory neuropathy occurred in 5% and febrile neutropenia in 0.5%. Grade >= 3 adverse events typical of bevacizumab were no more common than in phase III bevacizumab ovarian cancer trials. There was one case of gastrointestinal perforation (0.5%) and no treatment-related deaths. \Conclusion: OCTAVIA met its primary objective, demonstrating median PFS of approximately 2 years. This bevacizumab-containing regimen is active and tolerable.
Nyckelord
- Angiogenesis
- Bevacizumab
- Front-line
- Ovarian cancer
- Weekly paclitaxel
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Gonzalez-Martin, ...
-
Gladieff, Lauren ...
-
Tholander, Bengt
-
Stroyakovsky, Da ...
-
Gore, Martin
-
Scambia, Giovann ...
-
visa fler...
-
Kovalenko, Nadez ...
-
Oaknin, Ana
-
Ronco, Julian Pe ...
-
Freudensprung, U ...
-
Pignata, Sandro
-
visa färre...
- Artiklar i publikationen
-
European Journal ...
- Av lärosätet
-
Uppsala universitet